Join Festo on Saturday, February 3, 2018 at the campus of UC San Diego.
As laboratory experimentation, data and interpretation become increasingly complex, automation and information technology (IT) solutions become essential for successful drug discovery. The lab of the future will open unforeseen potential as higher throughput, precisely controlled automated processes; with smarter information collection and analysis, solve today's problems and bring new opportunities. The aspiration of this “future lab” is to empower scientists to simply perform the right experiment and bring new ideas to light. The Festo automation symposium will focus on how to make future laboratory solutions smarter to deliver more to science. Speakers from leading organizations will present a program focused on the fundamentals of the smart lab considering contributors such as Industry 4.0, Internet of Things (IoT), automated decision making, cloud processing and big data acquisition, with a special focus on sample handling and preparation.
This one day conference will provide an exclusive opportunity to network and be involved in inspiring and interesting discussions with opinion leaders in instrumentation, informatics, lab automation, strategy developers and industrial automation experts together with a strong and aligned vendor community. At the end of the conference, join us for a cocktail reception.
Dr. Michael Heller – University of California San Diego
Michael J. Heller received his Ph.D. in Biochemistry from Colorado State University (1973). He was an NIH Postdoctoral Fellow at Northwestern University (1973-1976). Dr. Heller was supervisor of the DNA Technology Group at Amoco Corporation, Standard Oil Indiana (1976 to 1984). He was Director of Molecular Biology at Molecular Biosystems (1984-1987). He was a co-founder of Integrated DNA Technologies, and served as President and Chief Operating Officer (1987-1989). He was a co-found of Nanotronics and Nanogen, and served as the Chief Technical Officer (1993-2001).
Dr. Heller is now a Professor in the Departments of Nanoengineering and Bioengineering at the University California San Diego. Recently he also co-founded a new company called Biological Dynamics, which is developing liquid biopsy cancer diagnostics. Dr. Heller has a respectable publication record; over 50 issued US patents and has been an invited speaker to a large number of scientific conferences and meetings.
Dr. Raj Krishnan – Bioligical Dynamics
Raj Krishnan, PhD founded Biological Dynamics in 2008 with the mission to revolutionize the approach toward the diagnosis and treatment of high burden diseases. Receiving his Ph.D. in Bioengineering from UC San Diego, Raj built a company based on the technology he developed for his dissertation, where he pioneered the use of AC Electrokinetics (ACE) for the purpose of blood-based diagnosis.
His passion has led Biological Dynamics through 3 rounds of funding. Raj has published several papers on ACE, was named to the Top 30 under 30 scientists by Forbes magazine and was on the Smart List for UK Wired magazine.
Dr. Douglas T. Gjerde - Phynexus
Dr. Gjerde Received in Ph.D. in Analytical Chemistry from Iowa State University in 1980. Prior to founding PhyNexus in 2002, Gjerde founded Sarasep, Inc. in 1990 and co-founded Transgenomic in 1997. Transgenomic achieved a successful IPO offering in 2000, three years after the company’s founding.
Dr. Gjerde has a broad range of research interests including polymer bead chemistry, organic chemistry, analytical chemistry, liquid chromatography, and molecular biology. In recent years, he has developed the theory and application for dual flow chromatography applied to automation for basic research and drug development. Dr. Gjerde is the co-author of more than 50 scientific journal publications, 90 patents and 6 books.
Paul Kendall - Festo
Paul is an industrial engineer by trade and has been involved in business development within industrial automation for nearly 25 years. During his career he has been involved in many industries including factory automation, process automation, food and beverage, printing and life sciences. Working within an international new markets group, Paul was heavily involved in the development of a market approach to the Lab Automation and Medical Device markets for Festo bringing together application knowhow with industrial automation robustness and best practice.
Today, he leads a strategic team to develop the GB market as well as continuing to support business development internationally and is focused on delivering high quality and technically leading solutions into the market as well as helping customers develop and maintain competitive advantage. Paul is an active board member for the ELRIG (European Laboratory Research Interest Group) and has been a member of the ELRIG General Committee since 2016.
David Dambman - Biosero
David is the architect of Biosero's Green Button Go automation scheduling software and leads the software and hardware development at Biosero.
His electric work experiences include aircraft maintenance data analysis and visualization projects, supply chain simulation and analysis, electronic warfare projects, as well as the manufacturing and design of guitar effects pedals.
Adam Snider - Perkin Elmer
Adam received his Bachelor of Science in Biochemistry from Tufts University in 2011. He worked for Quanterix Inc. in Lexington, MA and NABsys Inc. in Providence, RI before joining the Tripathi lab at Brown University.
He is now a 3rd year PhD candidate in Biomedical Engineering. His research focus is in microfluidic applications for next generation sequencing.
Neils Kruize - Synchron LabAutomation
Studied Biochemistry, did research on molecular microbiology and immunology. Worked for distributor of Life Science products in oligo synthesis, customer support and sales. Moved into robotics for molecular biology in the UK. Worked for KBioscience selling services, instruments and reagents for DNA extraction and SNP genotyping, acquired by LGC. Worked in phenotyping automation for two years.
Currently at Synchron, where we transition from making unique projects into standard AgBio products.